Masimo Corporation
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BT83V4
MASI
Masimo Corporation
GICS: 35101010
·
Sector: Healthcare
·
Sub-Sector: Medical Instruments & Supplies
NAME
Masimo Corporation
ISIN
US5747951003
TICKER
MASI
MIC
XNAS
REUTERS
MASI.OQ
BLOOMBERG
MASI US
F&G:
62
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 07.05.2025
Masimo
US5747951003
Masimo (NASDAQ: MASI) today announced that its management will participate in the BofA Securities 2025 Health Care Conference on Tuesday, May 13, 2025 at 4:20 p.m. Pacific time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
A...
Tue, 06.05.2025
Masimo
US5747951003
Masimo Corporation (Nasdaq: MASI), a leading global medical innovator, today announced that it has entered into a definitive agreement to sell its Sound United consumer audio business to HARMAN International (“HARMAN”), a wholly-owned subsidiary of Samsung Electronics Co., Ltd., for an aggregate purchase price of $350 million in cash, subject to c...
Tue, 06.05.2025
Masimo
US5747951003
Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 29, 2025.
First Quarter 2025 Results From Continuing Operations(1):
GAAP revenue of $372 million, representing 10% on a reported basis;
Non-GAAP revenue of $371 million, representing 10% on a constant currency basis(3);
GAAP net income ...
Thu, 24.04.2025
Masimo
US5747951003
Masimo (NASDAQ: MASI) will release first quarter 2025 financial results for the period ended March 29, 2025, after the market closes on Tuesday, May 6, 2025. The conference call to review the results will begin at 1:30 p.m. PT (4:30 p.m. ET) and will be hosted by Katie Szyman, Chief Executive Officer, and Micah Young, Chief Financial Officer.
To ...
Wed, 02.04.2025
Masimo
US5747951003
Masimo (NASDAQ: MASI) today announced that its management will participate in the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 2:15 p.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live present...
Fri, 28.02.2025
Masimo
US5747951003
Masimo (NASDAQ: MASI) today announced that its management will participate in the 46th Annual Raymond James Institutional Investor Conference on Tuesday, March 4, 2025 at 11:35 a.m. Eastern time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the liv...
Tue, 25.02.2025
Masimo
US5747951003
Masimo (Nasdaq: MASI) today announced its financial results for the fourth quarter and full-year ended December 28, 2024 and provided updated estimates for its full-year 2025 guidance.
Fourth Quarter 2024 Financial Results:
Consolidated revenue was $601 million, representing 9% growth on a reported and constant currency basis(1);
Healthcar...
Tue, 21.01.2025
Masimo
US5747951003
Today the Board of Directors (the “Board”) of Masimo (NASDAQ: MASI), a leading global medical innovator, announced that Katie Szyman has been appointed the next Chief Executive Officer (“CEO”) of the Company. Interim CEO Michelle Brennan has been appointed Chairman of Masimo’s Board and Lead Independent Director Quentin Koffey has been appointed V...
Thu, 16.01.2025
Masimo
US5747951003
Masimo Corporation (Nasdaq: MASI) today announced select preliminary financial results for the fourth quarter and full-year ended December 28, 2024 and provided estimates for its full-year 2025 guidance.
Preliminary Fourth Quarter 2024 Financial Results:
Consolidated revenue is expected to be approximately $601 million, representing 9% growth...
Tue, 14.01.2025
Masimo
US5747951003
The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Masimo Corporation (“Masimo” or the “Company”) (NASDAQ: MASI) concerning whether the board breached its fiduciary duties to shareholders.
If you are a shareholder, click here to participate.
Our investigation concerns whether the Company’s boar...
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
